Roberto Ferro Valdes, MD
Hematology & Oncology · Sioux Falls, SDNPI 1861780108
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AstraZeneca at 53.4% of the total. Reporting peaked in 2019 at $55,529 and has fallen 98.4% since, to $862 in 2025. Among hematology & oncology clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 406 payments — averaging $350.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$76K
- Astellas Pharma US Inc$20K
- AbbVie$12K
- Gilead$7K
- GSK$5K
- Genentech, Inc.$4K
- plus $18K from 54 others
Across 61 payments — averaging $5986.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$119K
- Novartis$95K
- Incyte Corporation$88K
- Takeda Pharmaceuticals U.S.A., Inc.$42K
- ADC Therapeutics America, Inc.$17K
- Merck$4K
What the payments were for
- Consulting fees$40,95529%
- Speaking & faculty fees$77,62355%
- Travel & lodging$14,16010%
- Food & beverage$9,3047%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$142,099 in reported general payments places this provider in the 90th percentile of 28 hematology & oncology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 61 | $925,410 |
| OjjaaraMomelotinib Dihydrochloride | 27 | $751,680 |
| RevlimidLenalidomide | 18 | $572,005 |
| CalquenceAcalabrutinib Maleate | 34 | $513,042 |
| OnuregAzacitidine | 12 | $314,736 |
| SprycelDasatinib | 14 | $247,369 |
| BesremiRopeginterferon Alfa-2b-Njft | 13 | $226,625 |
| VenclextaVenetoclax | 20 | $225,232 |
| BrukinsaZanubrutinib | 14 | $211,563 |
| JakafiRuxolitinib Phosphate | 11 | $190,607 |
| EliquisApixaban | 80 | $65,405 |
| XareltoRivaroxaban | 36 | $21,361 |
| Entecavir | 18 | $2,487 |
| Acyclovir | 109 | $975 |
| Ondansetron Hcl | 52 | $724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKOjjaara | $4,530 | $751,68027 claims |
| Bristol Myers SquibbRevlimid | $1,432 | $572,00518 claims |
| E.r. Squibb & Sons, L.L.C.Onureg, Sprycel | $3,423 | $562,10626 claims |
| AstraZenecaCalquence | $75,845 | $513,04234 claims |
| AbbVieVenclexta | $12,175 | $225,23220 claims |
| Beigene USA, Inc.Brukinsa | $125 | $211,56314 claims |
| Incyte CorporationJakafi | $274 | $190,60711 claims |
| PfizerEliquis | $234 | $65,40580 claims |
| Johnson & JohnsonXarelto | $260 | $21,36136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 28 hematology & oncology providers in South Dakota.
Other hematology & oncology in Sioux Falls
- Kelly McCaulSioux Falls$1.2M
- Waqas JehangirSioux Falls$23K
- Steven PowellSioux Falls$13K
- Benjamin SolomonSioux Falls$5K
- Miroslaw MazurczakSioux Falls$2K
- Mark HuberSioux Falls$1K
- Ryan VacaSioux Falls$1K
- Michael McHaleSioux Falls$811
- Heidi McKeanSioux Falls$552
- Allison WatsonSioux Falls$254
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.